RAP2C

Across TCGA pan-cancer cohorts, RAP2C Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAP2C data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher RAP2C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAP2C expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA and UCEC are the cancer types where RAP2C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.069	0.688	<.001	22	view →
UCEC	DFS	Median	All	0.939	0.617	.019	10	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RAP2C–BLCA (OS)

Open the BLCA breakdown →